Company Description
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions.
Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jun 25, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 211 |
| CEO | Stephen Gunstream |
Contact Details
Address: 2451 Bert Dr. Hollister, California 95023 United States | |
| Phone | 831 637 1100 |
| Website | teknova.com |
Stock Details
| Ticker Symbol | TKNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001850902 |
| CUSIP Number | 02080L102 |
| ISIN Number | US02080L1026 |
| Employer ID | 94-3368109 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Stephen Gunstream | President, Chief Executive Officer and Director |
| Matthew C. Lowell | Chief Financial Officer |
| Damon A. Terrill J.D. | General Counsel, Chief Compliance Officer and Secretary |
| Jennifer Henry | Senior Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Aug 30, 2024 | 424B3 | Prospectus |
| Aug 29, 2024 | EFFECT | Notice of Effectiveness |
| Aug 27, 2024 | UPLOAD | Filing |
| Aug 23, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 13, 2024 | 8-K | Current Report |
| Jul 22, 2024 | D | Notice of Exempt Offering of Securities |
| Jul 19, 2024 | SC 13D | General statement of acquisition of beneficial ownership |